Oral pivot redefines PNH: iptacopan's anaemia advantage reshapes switch dynamics while the orphan-drug exclusion keeps the anti-C5 price anchor intact.
Ravulizumab and eculizumab cover 60–70% of diagnosed US PNH patients, delivering strong haemolysis control via anti-C5 complement blockade. The clinical ceiling exposed by this class: 800–1,200 patients with extra-vascular haemolysis (EVH, persistent anaemia despite IV C5 therapy) represent the live commercial battleground. These patients transfuse on average two to three units per month and are iptacopan's primary switch target.
Iptacopan (Fabhalta, approved 2023) achieved 82.3% Hgb ≥2 g/dL response in EVH-dominant patients versus 2.0% comparator, redefining the treatment ceiling and establishing a new switch indication. Payer step-edit criteria from IV C5 to oral Factor B are forming; no major commercial payer had published a formal switch protocol as of mid-2024. The anti-C5 price anchor is not exposed to IRA Medicare negotiation: eculizumab and ravulizumab carry only orphan indications and are shielded by the orphan-drug exclusion (broadened by the 2025 OBBBA), with eculizumab further barred by approved biosimilars — so the class price holds rather than resetting.
Approved PNH agents — US, 2024
| Drug (Brand / INN) | Mechanism | Company | US Approval | Key Trial Result | Payer Routing |
|---|---|---|---|---|---|
| Ultomiris (ravulizumab) | Anti-C5 mAb IV q8w | AstraZeneca | Dec 2018 | 73.6% transfusion avoidance vs 15.1% (HERCULES) | Medicare Part B; tier 2 specialty commercial |
| Soliris (eculizumab) | Anti-C5 mAb IV q2w | AstraZeneca | Mar 2007 | 51% transfusion avoidance vs 0% (TRIUMPH) | Medicare Part B; declining share post-switch programme |
| Fabhalta (iptacopan) | Factor B inhibitor — oral | Novartis | Nov 2023 | 82.3% Hgb ≥2 g/dL vs 2.0% (APPLY-PNH) | Medicare Part D; PA forming; OOP differential vs Part B IV |
| Piasky (crovalimab) | Anti-C5 recycling mAb SC | Roche/Chugai | Jun 2024 | Non-inferior to eculizumab (COMMODORE 1&2) | Medicare Part B; SC self-injection reduces infusion centre cost |
Sources: FDA Drugs@FDA; NEJM APPLY-PNH (Risitano et al. 2023); HERCULES (Kulasekararaj et al. Blood 2019); ICER PNH Evidence Report (Iptacopan and Danicopan), March 2024.
What this brief answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- Current PA language at UHC, CVS/Aetna, and Cigna
- EVH clinical threshold
- anti-C5 inadequate response definitions payer by payer
Delivers
- Orphan-exclusion analysis for the anti-C5 class under the 2025 OBBBA
- biosimilar-driven eligibility bar for eculizumab
- pricing-parity analysis for IV vs oral absent a negotiated reset
Delivers
- Prescribing posture at top 20 US PNH centres
- early switch triggers and blockers
- EVH clinical recognition gaps
Custom brief delivered in 72 hours.
Commission This BriefWhat's inside
- Why ravulizumab and eculizumab together cover 60 to 70% of diagnosed US PNH patients through anti-C5 complement blockade.
- How roughly 1,000 EVH-dominant patients, transfusing two to three units monthly, define the live commercial battleground.
- Why Ultomiris's 73.6% transfusion avoidance in HERCULES far exceeds Soliris's 51% result from the earlier TRIUMPH trial.
- How Piasky's subcutaneous self-injection, shown non-inferior to eculizumab in COMMODORE 1 and 2, cuts infusion centre costs.
- Why iptacopan's 82.3% Hgb response rate versus just 2.0% for anti-C5 background redefines the treatment ceiling for EVH patients.
- How patients transfusing two to three units per month despite IV C5 therapy became iptacopan's primary switch target.
- Why no major commercial payer had published a formal IV-to-oral switch protocol for iptacopan as of mid-2024.
- How Fabhalta's Medicare Part D routing creates an out-of-pocket differential against Ultomiris and Soliris under Part B.
- Why the 2025 OBBBA's broadened orphan-drug exclusion keeps ravulizumab and eculizumab out of IRA Medicare price negotiation.
- How eculizumab's approved biosimilars create a separate eligibility bar that further shields the anti-C5 price anchor.
- Why prescribing posture at the top 20 US PNH centres determines how quickly iptacopan adoption spreads beyond early adopters.
- How gaps in clinical recognition of EVH symptoms among prescribers still block or accelerate switches from Ultomiris.
Included with every brief
How AXLRx builds this brief
Prepared by MoatRx analysts.
Every AXLRx brief is built from primary regulatory sources (FDA, ClinicalTrials.gov), peer-reviewed literature, and live payer policy documentation — not secondary summaries. Findings are independently verified before inclusion.
PNH CI sources: FDA Drugs@FDA, APPLY-PNH NEJM 2023, HERCULES Blood 2019, COMMODORE NEJM 2023, ICER PNH Evidence Report (March 2024), CMS Medicare Drug Price Negotiation selected-drug lists (IPAY 2026–2028), and major payer PA policy documents (UHC, CVS/Aetna, Cigna).
- Drug approval dates verified against FDA Drugs@FDA database
- Clinical trial results verified against published primary sources (NEJM, Blood)
- Payer PA criteria verified against current payer coverage policy documents
- IRA status verified against CMS published selected-drug lists (IPAY 2026–2028) and OBBBA orphan-exclusion guidance
Frequently asked questions
Commission this brief
AXLRx delivers PNH competitive intelligence built for pharma and biotech commercial, access, and medical affairs teams. Custom brief in 72 hours.
Use the intake form to specify your indication, geography, and commercial question.
AXLRx analyst confirms scope, comparators, and delivery format.
Research-verified brief in 72 hours with optional analyst readout.